TickerFactsScreenerDevelopers

Ultragenyx Pharmaceutical Inc. (RARE) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2011: $10.64M2012: $86.19M2013: $7.43M2014: $24.32M2015: $93.57M2016: $161.12M2017: $100.49M2018: $113.43M2019: $433.58M2020: $713.53M2021: $307.58M2022: $132.94M2023: $214.00M2024: $174.00M2025: $421.00M$421.00M
2011Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$421.00M+142.0%
2024$174.00M-18.7%
2023$214.00M+61.0%
2022$132.94M-56.8%
2021$307.58M-56.9%
2020$713.53M+64.6%
2019$433.58M+282.2%
2018$113.43M+12.9%
2017$100.49M-37.6%
2016$161.12M+72.2%
2015$93.57M+284.7%
2014$24.32M+227.5%
2013$7.43M-91.4%
2012$86.19M+709.7%
2011$10.64M—